Important Notice: Our web hosting provider recently started charging us for additional visits, which was unexpected. In response, we're seeking donations. Depending on the situation, we may explore different monetization options for our Community and Expert Contributors. It's crucial to provide more returns for their expertise and offer more Expert Validated Answers or AI Validated Answers. Learn more about our hosting issue here.

What are the Needs in the Drug Discovery Space Addressable via Pathway Maps?

0
Posted

What are the Needs in the Drug Discovery Space Addressable via Pathway Maps?

0

There is a huge amount of interest currently in the drug discovery community in using small interfering RNA (variously termed RNAi or siRNA) molecules as a means to knock down the levels of proteins in cells. In this manner, researchers can attempt to simulate biological scenarios whereby cellular interactions with drug candidates, for example, can be studied in biologically relevant situations in vivo. The important point here is that RNAi-based gene knockdown is a way to gently perturb a biologically pathway in vivo without actually effecting gross changes in the biology of the system under study. Target validation, the concept of characterizing biological targets for their amenability to be druggable (i.e., for small molecule drug candidates to affect their function in vivo), is a key problem in the drug discovery space. Indeed, it is a bottleneck, given the large number of potential targets emanating from the human genome and the relatively small fraction thereof that are actually

Thanksgiving questions

*Sadly, we had to bring back ads too. Hopefully more targeted.